Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    5

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,586.7015.300.18%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,601.2656.950.24%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,160.47174.600.47%
NZX 50 Index12,596.5065.75-0.52%
S&P 5005,802.8339.18-0.67%
S&P/ASX 2008,360.9012.200.15%
SSE Composite Index3,348.3731.82-0.94%

Market Movers